OneNeb

Analysis of biodiesel and oil samples by on-line calibration using a Flow Blurring® multinebulizer in ICP OES without oxygen addition

A new multinebulizer, based on Flow Blurring® technology (FBMN), is evaluated for a simple, fast and direct analysis of organic samples in Inductively Coupled Plasma Optical Emission Spectrometry (ICP OES)

The successful study published in the Journal of Analytical Atomic Spectrometry has been developed in the Analytical Chemistry, Nutrition and Food Science Department and Institute of Materials of the University of Alicante led by Professor Antonio Canals and his team

For further information click here

TFIIS is required for the balanced expression of the genes encoding ribosomal components under transcriptional stress. Researchers utilized Cellena

Fernando Gómez-Herreros, Lola de Miguel-Jiménez, Macarena Morillo-Huesca, Lidia Delgado-Ramos, María C. Muñoz-Centeno and Sebastián Chávez*
Departamento de Genética, Facultad de Biología, Universidad de Sevilla, Avda Reina Mercedes 6. E-41012 Seville, Spain
Received February 18, 2011; Revised April 4, 2012; Accepted April 5, 2012

ABSTRACT
Transcription factor IIS (TFIIS) stimulates RNA cleavage by RNA polymerase II by allowing backtracked enzymes to resume transcription elongation.
Yeast cells do not require TFIIS for viability, unless ,they suffer severe transcriptional stress due to NTP-depleting drugs

like 6-azauracil ormycophenolic acid. In order to broaden our knowledge on the role of TFIIS under transcriptional stress, we carried out a genetic screening for suppressors of TFIIS-lacking cells’ sensitivity to 6-azauracil and mycophenolic acid. Five suppressors were identified, four of which were related to the transcriptional regulation of those genes encoding ribosomal components [rRNAs and ribosomal proteins (RP)], including global regulator SFP1. This led us to discover that RNA polymerase II
is hypersensitive to the absence of TFIIS under NTP iscarcity conditions when transcribing RP genes. The absence of Sfp1 led to a profound alteration of the transcriptional response to NTP-depletion, thus allowing the expression of RP genes to resist these
stressful conditions in the absence of TFIIS. We discuss the effect of transcriptional stress on ribosome biogenesis and propose that TFIIS contributes to prevent a transcriptional imbalance between rDNA and RP gene.

 

Read the complete paper here

Biomedal and Ingeniatrics signs a distribution agreement for Cellena® bioencapsulator.

Biomedal SL and Ingeniatrics have signed a strategic distribution agreement. Biomedal will be the global distributor of Ingeniatric's portable Bioencapsulation device, Cellena®. The agreement was signed on Friday, March 16^th at Ingeniatrics’s facilities by both companies CEOs Dr. Angel Cebolla Ramirez, Biomedal, and Mr. Joaquin Gómez Moya, Ingeniatrics.

Biomedal:

Cellena® is a user-friendly, portable device that makes unneeded the use of autoclave as it is provided with sterile disposable nozzles. Nonetheless it is aimed to a highly specialized market: e.g. stem cells researchers; it is a complex sales process that requires a distributor like Biomedal. This is a well known biotechnology company with a seasoned sales force and whose mission is to develop and commercialize new biomedical technologies, services and products for research, bioindustry and diagnostics. Biomedal enhances the talent of its team with the collaboration of an outstanding and growing network of international scientists and technologists, and directs its efforts to satisfy its customers.

The excellent market position of this company based in Seville ensures short-term success in Emerging markets as cell therapy or stem cell research

Bioencapsulation Step forward

“This agreement confirms the Ingeniatrics effort  to settle down as one of the main microencapsulation key-players. Cellena® would improve some assays and diagnostics in an order of magnitude and can be utilized in combination with cytometers like - for instance - COPAS and Biosorter” indicated Ángel Cebolla.

Biomedal will offer this device among other products to improve the society quality of life and has started proposing Bioencapsulation as a cost-effective solution to the some of the most important research groups in the world. On the other hand, Ingeniatrics still owns the Flow Focusing® technology and stays sole manufacturer of Cellena®.

For further information please click here

Catálogo Interactivo de la OTRI

La Oficina de Transferencia de Resultados de Investigación (OTRI) ha elaborando un catálogo acerca de las Spin off de la Universidad de Sevilla.Este catálogo pretende hacer lo más atractiva posible la información publicada de cada compañía, destacando el origen tecnológico de las mismas y haciendo especial hincapié en patentes, servicios, productos y proyectos de investigación.

"Desde el Vicerectorado de Transferencia Tecnológica de la Universidad de Sevilla se han impulsado actuaciones que falicitan la valorización del conocimiento generado por la Universidad, favoreciendo el proceso de transferencia de conocimeinto universitario a la sociedad y dando especial relevancia  a la creación de empresas Spin Off como herramienta eficaz de aplicación del conocimiento generado en la institución"

Para más información, pinche aqui
 

AENOR certificates Ingeniatrics' Quality Control and Environment management according to ISO 9001 and 14001.

Lola Romero Guzmán, Ingeniatrics's QA & Environment Manager.

On March 2012, the technological company Ingeniatrics, specialized in design and production of micro and nano particles and the equipment to produce them, has attained ISO 9001 and ISO 14001 certificates issued by AENOR, acknowledging that Ingeniatrics’ environmental and quality management systems fully meet international requirements according to UNE-EN-ISO 9001:2008 and UNE-EN-ISO 14001:2004 after the corresponding audits.

AENOR:

The audit was carried out by a team of AENOR, Asociación Española de Normalización y Acreditación, which is in possession of close to 190 national and international accreditations including ENAC's. ENAC is the Spanish Accreditation Body which in turns belongs the international quality certification accreditation system and is recognized in the UE, EFTA, USA, Canada, Japan, China, Australia... Up to 60 countries.

Continuous improvement in the long run:

Pilot plant’s construction ended in December 2011, so validation tests, operational and procedures qualification started up immediately after that. Simultaneously quality control projects had started on March 2011, going through different phases of study, project, documentation, procedures definition, procedures deployment, reviews, mandatory pre-auditory and finally - on December 2011 and January 2012 - the audit itself.  

Ingeniatrics' quality control and environmental management was led by Lola Romero who indicates “this milestone is not the end, but the beginning of a way of continuous improvement which reaffirms the company position in the market”. Ingeniatrics' principals have targeted chemical, pharmaceutical and food major corporations interested in the applications of Flow Focusing and Flow Blurring microparticles technology.

Scope:

Certification for pharma field is in progress. Current certificate scope is: "Provision of microencapsulation services for Chemicals and Nutrition industries. Design and manufacturing of micro- and nano- particles. Design and manufacturing of nebulizers and atomization systems."

Ingeniatrics and Aradigm sign a licensing agreement to apply Flow Focusing® and Flow Blurring® technology to inhalation drugs.

The technological Ingeniatrics and Aradigm, a pulmonary pharmaceutical industry pioneer, signed a new agreement in February, 2012. By this, Aradigm is licensed by Ingeniatrics to develop and operate in the field of medicaments administration to or through respiratory tract using flow focusing and flow blurring technology. 

Aradigm:

Aradigm's multidisciplinary team led by Dr. Igor Gonda and David Cipolla has experience at developing a variety of pharmaceutical and health care products and launching them to the market.

Aradigm gets an exclusive, world-wide license on Ingeniatrics's technology to develop, make, use, sell, and  offer for sale drugs delivered by inhalation, including drugs for  severe respiratory disease treatment.

 

Enhanced Licensees support:

Once Ingeniatrics had reached agreements with Flow Pharma and the University of Seville, this agreement with Aradigm confirms Ingeniatrics’ control and strengthen its position. Due to this, the microencapsulation company offers a stable, safe and simplified framework to all its licensees and their sub- licensees in order to ensure their business model.

 

 

Optimized Intellectual Property management:

 

Ingeniatrics is currently focused on scaling its technologies up, enhancing its capacity to offer services and products making use of its brand-new three hundred square meters microencapsulation pilot-plant, which is made up of three separate rooms for Pharma (registered as "cleanroom" or ISO 7 white room), Food and Chemistry.

By virtue of this agreement, Ingeniatrics will be the only Flow Focusing^® and Flow Blurring^® patents manager world-wide. Alongside with other previous agreements, this one grants to Ingeniatrics a solid base to strategize the best course of action to protect its microencapsulation and nebulization Intellectual Property.